Open AccessDesign and Baseline Characteristics of the Chlorthalidone in Chronic Kidney Disease (CLICK) Trial
Author(s) -
Rajiv Agarwal,
Andrew E. Cramer,
Mary Balmes-Fenwick,
Arjun Sinha,
Fangqian Ouyang,
Wanzhu Tu
Publication year - 2020
Publication title -
american journal of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 85
eISSN - 1421-9670
pISSN - 0250-8095
DOI - 10.1159/000508700
Subject(s) - medicine , chlorthalidone , kidney disease , diuretic , placebo , blood pressure , loop diuretic , ambulatory blood pressure , randomized controlled trial , randomization , thiazide , urology , endocrinology , gastroenterology , pathology , alternative medicine
Hypertension often accompanies chronic kidney disease (CKD), and diuretics are widely prescribed to reduce blood pressure (BP). Chlorthalidone (CTD) is a thiazide-like diuretic and an effective antihypertensive drug, yet little data exist to support its use in treating hypertension in individuals with advanced CKD.